After Searing Debate, FDA Clears Unproven Sarepta Drug

By Jeff Overley (September 19, 2016, 10:19 PM EDT) -- The U.S. Food and Drug Administration on Monday cleared a $300,000 drug from Sarepta Therapeutics for muscular dystrophy despite unproven benefits, capping an extraordinary review process that saw the agency's top drug regulator overrule scientists who opposed approval....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!